“…ABCC1 is also able to confer resistance to many chemotherapeutic agents, such as anthracyclines (e.g., doxorubicin) and the folate antagonist methotrexate. Indeed, clinical studies have demonstrated that overexpression of ABCC1 in a variety of solid or invasive tumors, such as breast, ovarian, lung, prostate, and neuroblastoma, is implicated as a high risk factor of MDR and is a negative prognostic biomarker (Filipits et al, 2005;Haber et al, 2006;Triller et al, 2006;Faggad et al, 2009). For example, ABCC1 is readily detectable in all primary neuroblastoma samples studied, and a greater degree of ABCC1 expression is highly predictive of both event-free survival and overall patient survival (Haber et al, 2006).…”